Barbara Gayle Duncan - Apr 25, 2024 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role: Director
Signature: /s/ James Oehler, Attorney-in-Fact
Stock symbol: HALO
Transactions as of: Apr 25, 2024
Transactions value $: $0
Form type: 4
Date filed: 4/29/2024, 05:54 PM
Previous filing: Feb 26, 2024
Next filing: Jun 4, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	Price $	Shares After	Date	Ownership	Footnotes
transaction	HALO	Common Stock	Award	$0	+6.5K	+70.26%	$0.00	15.8K	Apr 25, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HALO	Option to Purchase Common Stock	Award	$0	+8.8K		$0.00	8.8K	Apr 25, 2024	Common Stock	8.8K	$38.46	Direct	F2

Explanation of Responses:

Id	Content
F1	Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.
F2	Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders.

Content

Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.

Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders.